M
Mark N. Stein
Researcher at Columbia University Medical Center
Publications - 205
Citations - 7201
Mark N. Stein is an academic researcher from Columbia University Medical Center. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 37, co-authored 185 publications receiving 5395 citations. Previous affiliations of Mark N. Stein include Rutgers University & Columbia University.
Papers
More filters
Journal ArticleDOI
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher,Michael J. Morris,Walter M. Stadler,Celestia S. Higano,Ethan Basch,Karim Fizazi,Emmanuel S. Antonarakis,Tomasz M. Beer,Michael A. Carducci,Kim N. Chi,Paul G. Corn,Johann S. de Bono,Robert Dreicer,Daniel J. George,Elisabeth I. Heath,Maha Hussain,Wm. Kevin Kelly,Glenn Liu,Christopher J. Logothetis,David M. Nanus,Mark N. Stein,Dana E. Rathkopf,Susan F. Slovin,Charles J. Ryan,Oliver Sartor,Eric J. Small,Matthew R. Smith,Cora N. Sternberg,Mary-Ellen Taplin,George Wilding,Peter S. Nelson,Lawrence H. Schwartz,Susan Halabi,Philip W. Kantoff,Andrew J. Armstrong +34 more
TL;DR: The concept of no longer clinically benefiting is introduced to underscore the distinction between first evidence of progression and the clinical need to terminate or change treatment, and the importance of documenting progression in existing lesions as distinct from the development of new lesions.
Journal ArticleDOI
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Toni K. Choueiri,Ulka N. Vaishampayan,Jonathan E. Rosenberg,Theodore F. Logan,Andrea L. Harzstark,Ronald M. Bukowski,Brian I. Rini,Sandy Srinivas,Mark N. Stein,Laurel M. Adams,Lone Ottesen,Kevin H. Laubscher,Laurie Sherman,David F. McDermott,Naomi B. Haas,Keith T. Flaherty,Robert S. Ross,Peter D. Eisenberg,Paul S. Meltzer,Maria J. Merino,Donald P. Bottaro,W. Marston Linehan,Ramaprasad Srinivasan +22 more
TL;DR: Frentinib demonstrated activity in patients with advanced PRCC with a manageable toxicity profile and a high response rate in patientsWith germline MET mutations, the presence of a germlineMET mutation was highly predictive of a response.
Journal ArticleDOI
A phase I dose-escalation trial of 2-deoxy- d -glucose alone or combined with docetaxel in patients with advanced solid tumors
Luis E. Raez,Kyriakos P. Papadopoulos,A. Ricart,E. Gabriella Chiorean,Robert S. DiPaola,Mark N. Stein,Caio Max S. Rocha Lima,James J. Schlesselman,Khaled A. Tolba,V. K. Langmuir,Stewart Kroll,Donald Jung,Metin Kurtoglu,Joseph D. Rosenblatt,Theodore J. Lampidis +14 more
TL;DR: The recommended dose of 2DG in combination with weekly docetaxel is 63 mg/kg/day with tolerable adverse effects, and this phase I trial found this to be the clinically tolerable dose.
Journal ArticleDOI
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Janice M. Mehnert,Anshuman Panda,Hua Zhong,Hua Zhong,Kim M. Hirshfield,Sherri Damare,Katherine Lane,Levi Sokol,Mark N. Stein,Lorna Rodriguez-Rodriquez,Howard L. Kaufman,Siraj M. Ali,Jeffrey S. Ross,Dean Pavlick,Gyan Bhanot,Eileen White,Robert S. DiPaola,Ann Lovell,Jonathan D. Cheng,Shridar Ganesan +19 more
TL;DR: Analysis of The Cancer Genome Atlas revealed that the presence of POLE mutation associates with high mutational burden and elevated expression of several immune checkpoint genes, which suggest that cancers harboring POLE mutations are good candidates for immune checkpoint inhibitor therapy.
Journal ArticleDOI
Contemporary risk profile of prostate cancer in the United States
Yu-Hsuan Shao,Kitaw Demissie,Weichung Shih,Amit R. Mehta,Mark N. Stein,Calpurnyia B. Roberts,Robert S. DiPaola,Grace L. Lu-Yao +7 more
TL;DR: More men were diagnosed with prostate cancer at a younger age and earlier stage in 2004-2005 than in earlier years and the racial disparity in cancer stage at diagnosis has decreased statistically significantly over time.